T Therapeutics Appoints Kirsty Crame Chief Development Officer

Company T-Therapeutics Event Type Leadership appointment Modality TCR-CD3 bispecific T-cell engagers Asset Undisclosed lead programs Target Peptide-HLA complexes; CD3 Disease Area Oncology; autoimmune disease Summary T-Therapeutics announced on November 5 that Kirsty Crame joined as chief development officer to oversee translational and clinical development alongside…